COMP <GO>
EWTX vs LQDA // RSI-14 & 200D SMA MOMENTUM
Edgewise Therapeutics Inc. (NASDAQ) VS. Liquidia Corporation (NASDAQ) • 15-METRIC TALLY: EWTX 5
— LQDA 6
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LQDA
LAST: $38.11 (-2.03%) • MKT CAP: $4.22B
rsi-technicals
45.7
LAST: $41.85 (-7.12%) • MKT CAP: $4.03B
rsi-technicals
52.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EWTX VS. LQDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EWTX | LQDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.90% | -12.60% | -19.30 | LQDA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.41% | -0.99% | -2.42 | LQDA | /fcf-yield <GO> |
| Operating Margin | -16.20% | -32.50% | +16.30 | EWTX | /operating-margins <GO> |
| Net Profit Margin | 0.00% | -43.50% | +43.50 | EWTX | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 180.00% | -181.10 | LQDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.33 | +19.67 | EWTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | LQDA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 45.7 | 52.5 | -6.80 | LQDA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.90 | +0.20 | EWTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 21.0x | +4.00 | LQDA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.22B | $4.03B | $191.4M | EWTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EWTX REV | LQDA REV | EWTX GROSS % | LQDA GROSS % | EWTX FCF | LQDA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $535.9M | $158.3M | — | — | -$144.1M | -$40.0M |
| FY 2024 | $444.7M | $14.0M | — | 58.0% | -$110.3M | -$98.4M |
| FY 2023 | $320.2M | $17.5M | — | — | -$91.9M | -$42.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EWTX // BETA 1.10
LQDA // BETA 0.90